arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Jade Biosciences, Inc.

JBIO Health Care Biotechnology: Pharmaceutical Preparations
$14.79
▼ -2.2% Today
as of Oct 23, 13:48 ET
Last 30 days -19.09% Sep 14 → Oct 23
$13.03 $14.41 $15.80 $17.18 $18.56 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$15.04
High
$15.44
Low
$14.36
Volume
$575,925
Avg Vol
$678,888
Mkt Cap
$876M
P/E (TTM)
—
Beta
—
52w High
$28.00
52w Low
$8.36
Div Yield
—
Shares Out
$64M

Recent Press Releases & News last 60 days · 3 items

Oct 21 · 11:00 PR GlobeNewswire
Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026
Sep 30 · 11:00 PR GlobeNewswire
Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
Sep 1 · 11:00 PR GlobeNewswire
Jade Biosciences to Participate in Upcoming Conferences

JBIO earnings at a glance

The options market is pricing a move of about ±35.3% after the report, a range of roughly $9.56 to $20.02 from today's $14.79. Over its last 2 reports the stock rose the next day 0 times and fell 2, moving ±2.5% on average; after the most recent report on May 7, 2026 it moved -3.6%. That means options currently expect more movement than JBIO has typically delivered. JBIO beat the consensus EPS estimate in 2 of its last 4 reported quarters. Implied volatility is currently 299%. The share price of $14.79 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$8.36
$28
33% of range
Avg surprise (last 4)
-6.0%
Avg reaction (last 2)
-2.5%
0% positive
Latest IV / EM
299%
EM ±35.3% · $15 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-5.16$-3.89$-2.62$-1.36$-0.09 Actual $-0.67Actual $-0.76Actual $-0.71Actual $-0.83Actual $-0.86Actual $-5.16Actual $-0.09Est $-0.30Actual $-0.86Est $-0.43Actual $-0.48Est $-0.57Actual $-0.57Est $-0.52Actual $-0.76 MarJunSepMarJunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-56M$-46M$-36M$-27M$-17M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.76 — — — — financials
Thu May 7, 2026Mar/2026 $-0.57 $-0.52 -9.6% -533.3% -3.6% earnings
Thu Nov 13, 2025Sep/2025 $-0.48 $-0.57 +15.8% — — earnings
Wed Aug 13, 2025Jun/2025 $-0.86 $-0.43 -100.0% — — earnings
Fri Apr 25, 2025Mar/2025 $-0.09 $-0.30 +70.0% — -1.5% earnings
Mon Sep 30, 2024Sep 2024 $-5.16 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.86 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.83 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.71 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.76 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.67 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-59M$-43M—$-27M$-28M$-23M—$-15M
Net income$-56M$-40M—$-25M$-32M$-38M—$-16M
EPS (diluted)$-0.76$-0.57—$-0.48$-0.86$-12.10—$-5.16

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$107M$55M$88M$50M$221M$44M$69M$31M
Inventory————————
Total current assets$471M$319M$349M$201M$223M$77M$70M$91M
Total assets$472M$319M$350M$202M$224M$78M$73M$91M
Long-term debt————————
Total liabilities$32M$23M$17M$23M$22M$2M$120M$10M
Total equity$440M$296M$333M$179M$202M$-84M$-47M$-17M

Implied volatility — last 90 days

58%221%385%549%712% Jun 08 — IV 263% · EM ±34.7%Jun 10 — IV 277% · EM ±32.8%Jun 16 — IV 523% · EM ±30.9%Jun 17 — IV 713% · EM ±29.8%Jun 22 — IV 108% · EM ±22.6%Jun 23 — IV 116% · EM ±23.7%Jun 24 — IV 115% · EM ±23.0%Jun 25 — IV 127% · EM ±24.9%Jun 26 — IV 119% · EM ±22.7%Jun 29 — IV 128% · EM ±22.6%Jun 30 — IV 131% · EM ±22.5%Jul 01 — IV 137% · EM ±22.9%Jul 02 — IV 155% · EM ±25.1%Jul 03 — IV 161% · EM ±25.1%Jul 06 — IV 169% · EM ±23.5%Jul 07 — IV 178% · EM ±23.5%Jul 09 — IV 188% · EM ±22.2%Jul 10 — IV 216% · EM ±23.9%Jul 13 — IV 304% · EM ±25.4%Jul 14 — IV 324% · EM ±23.4%Jul 15 — IV 387% · EM ±22.9%Jul 20 — IV 121% · EM ±28.5%Jul 21 — IV 107% · EM ±24.8%Jul 22 — IV 98% · EM ±22.4%Jul 24 — IV 114% · EM ±25.1%Jul 27 — IV 122% · EM ±25.6%Jul 28 — IV 127% · EM ±25.9%Jul 29 — IV 132% · EM ±26.4%Jul 30 — IV 119% · EM ±23.4%Jul 31 — IV 134% · EM ±25.6%Aug 03 — IV 149% · EM ±26.4%Aug 04 — IV 163% · EM ±28.1%Aug 05 — IV 143% · EM ±24.0%Aug 06 — IV 139% · EM ±22.5%Aug 10 — IV 166% · EM ±23.0%Aug 11 — IV 169% · EM ±22.4%Aug 12 — IV 180% · EM ±22.6%Aug 13 — IV 165% · EM ±19.5%Aug 14 — IV 183% · EM ±20.2%Aug 17 — IV 255% · EM ±21.3%Aug 18 — IV 294% · EM ±21.2%Aug 19 — IV 212% · EM ±12.5%Aug 20 — IV 620% · EM ±25.9%Aug 24 — IV 122% · EM ±25.4%Aug 25 — IV 58% · EM ±11.9%Aug 26 — IV 126% · EM ±25.3%Aug 27 — IV 129% · EM ±25.4%Aug 28 — IV 81% · EM ±15.5%Aug 31 — IV 132% · EM ±23.4%Sep 01 — IV 141% · EM ±24.3%Sep 02 — IV 140% · EM ±23.4%Sep 03 — IV 111% · EM ±18.0%Sep 08 — IV 86% · EM ±11.3%Sep 11 — IV 253% · EM ±27.9%Sep 15 — IV 76% · EM ±5.5%Sep 21 — IV 97% · EM ±20.2%Sep 23 — IV 78% · EM ±15.6%Sep 24 — IV 82% · EM ±16.1%Oct 01 — IV 132% · EM ±21.4%Oct 08 — IV 299% · EM ±35.3%

Sector peers

CRVS
Corvus Pharmaceuticals, Inc.
$876M $10.37+3.2%
TBPH
Theravance Biopharma, Inc.
$880M $17.030.0%
HELP
Helus Pharma Inc.
$870M $9.96-7.6%
ABUS
Arbutus Biopharma Corporation
$902M $4.21+0.6%
MLTX
MoonLake Immunotherapeutics
$917M $11.76+10.4%
ESPR
Esperion Therapeutics, Inc.
$819M $3.18

JBIO earnings FAQ

What is JBIO's expected move for earnings?

Options currently price a move of about ±35.3%, or $5.23 per share either way from $14.79.

How does JBIO stock usually react to earnings?

Across the last 2 reports the average next-day move was ±2.5%, up 0 times and down 2 times.

What is JBIO's implied volatility?

JBIO's at-the-money implied volatility is about 299% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in